rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    FBRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Forte Biosciences Completed Take-Private Merger and Delisting

      Tipranks Press Release.

      Aug 28The Globe and MailFBRX
      Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition

      argenx (ENXTBR:ARGX) has completed its acquisition of Forte Biosciences, adding antibody candidate FB102 to its immunology pipeline. The transaction supports argenx's Vision 2030 plan to broaden its presence in autoimmune disease treatment. FB102 is expected to be integrated into argenx's existing research and development programs focused on immunology. For readers who want more ideas in advanced immunology and related technologies, the next step is to explore 134 healthcare AI...

      Aug 27Yahoo FinanceARGXFBRX
      argenx completes acquisition of Forte Biosciences for $77 per share
      Aug 27Investing.comARGXFBRX
      argenx Completes Acquisition of Forte Biosciences, Inc.

      Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline

      Aug 27BarchartFBRX
      Argenx Completes Acquisition of Forte Biosciences
      Aug 27Yahoo FinanceFBRX
      Forte Biosciences earnings on deck as argenx deal looms
      Aug 23Investing.comARGXFBRX

      This is the newest page. Registered accounts read further back.